Prior to Aldea, he was Senior Vice President of Corporate Development and Licensing for Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.), where he was responsible for the consummation of over 30 ...

$3.9 billion was wiped off Sepracor's market capitalization as investors called into question the entire utility of single enantiomers as a means of improving drugs and managing product life cycles.